Hepatic Stellate Cells Promote Hepatocyte Engraftment in Rat Liver After Prostaglandin-Endoperoxide Synthase Inhibition

Yuta Enami, Sriram Bandi, Sorabh Kapoor, Natan Krohn, Brigid Joseph, Sanjeev Gupta

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background & Aims: Hepatic inflammation occurs immediately after cells are transplanted to the liver, but the mechanisms that underlie this process are not fully defined. We examined cyclooxygenase pathways that mediate hepatic inflammation through synthesis of prostaglandins, prostacyclins, thromboxanes, and other prostanoids following transplantation of hepatocytes. Methods: We transplanted F344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient F344 rats. Changes in cyclooxygenase pathways were analyzed, and specific pathways were blocked pharmacologically; the effects on cell engraftment and native liver cells were determined. Results: Transplantation of hepatocytes induced hepatic expression of prostaglandin-endoperoxide synthases 1 and 2, which catalyze production of prostaglandin H2, as well as the downstream factor thromboxane synthase, which produces thromboxane A2 (a regulator of vascular and platelet responses in inflammation). Transplanted hepatocytes were in proximity with liver cells that expressed prostaglandin-endoperoxide synthases. The number of engrafted hepatocytes increased in rats given naproxen or celecoxib before transplantation but not in rats given furegrelate (an inhibitor of thromboxane synthase) or clopodigrel (an antiplatelet drug). Naproxen and celecoxib did not prevent hepatic ischemia or activation of neutrophils, Kupffer cells, or inflammatory cytokines, but they did induce hepatic stellate cells to express cytoprotective genes, vascular endothelial growth factor and hepatocyte growth factor, and matrix-type metalloproteinases and tissue inhibitor of metalloproteinase-1, which regulate hepatic remodeling. Conclusions: Activation of cyclooxygenase pathways interferes with engraftment of transplanted hepatocytes in the liver. Pharmacologic blockade of prostaglandin-endoperoxide synthases stimulated hepatic stellate cells and improved cell engraftment.

Original languageEnglish (US)
Pages (from-to)2356-2364
Number of pages9
JournalGastroenterology
Volume136
Issue number7
DOIs
StatePublished - Jun 2009

Fingerprint

Hepatic Stellate Cells
Prostaglandin-Endoperoxide Synthases
Hepatocytes
Liver
Celecoxib
Thromboxanes
Naproxen
Transplantation
Inbred F344 Rats
Inflammation
Prostaglandins
Prostaglandins I
Prostaglandin H2
Dipeptidyl Peptidase 4
Neutrophil Activation
Thromboxane A2
Tissue Inhibitor of Metalloproteinase-1
Kupffer Cells
Matrix Metalloproteinase Inhibitors
Hepatocyte Growth Factor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatic Stellate Cells Promote Hepatocyte Engraftment in Rat Liver After Prostaglandin-Endoperoxide Synthase Inhibition. / Enami, Yuta; Bandi, Sriram; Kapoor, Sorabh; Krohn, Natan; Joseph, Brigid; Gupta, Sanjeev.

In: Gastroenterology, Vol. 136, No. 7, 06.2009, p. 2356-2364.

Research output: Contribution to journalArticle

Enami, Yuta ; Bandi, Sriram ; Kapoor, Sorabh ; Krohn, Natan ; Joseph, Brigid ; Gupta, Sanjeev. / Hepatic Stellate Cells Promote Hepatocyte Engraftment in Rat Liver After Prostaglandin-Endoperoxide Synthase Inhibition. In: Gastroenterology. 2009 ; Vol. 136, No. 7. pp. 2356-2364.
@article{48b2c208c38c4795b8fa33deb0e936ad,
title = "Hepatic Stellate Cells Promote Hepatocyte Engraftment in Rat Liver After Prostaglandin-Endoperoxide Synthase Inhibition",
abstract = "Background & Aims: Hepatic inflammation occurs immediately after cells are transplanted to the liver, but the mechanisms that underlie this process are not fully defined. We examined cyclooxygenase pathways that mediate hepatic inflammation through synthesis of prostaglandins, prostacyclins, thromboxanes, and other prostanoids following transplantation of hepatocytes. Methods: We transplanted F344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient F344 rats. Changes in cyclooxygenase pathways were analyzed, and specific pathways were blocked pharmacologically; the effects on cell engraftment and native liver cells were determined. Results: Transplantation of hepatocytes induced hepatic expression of prostaglandin-endoperoxide synthases 1 and 2, which catalyze production of prostaglandin H2, as well as the downstream factor thromboxane synthase, which produces thromboxane A2 (a regulator of vascular and platelet responses in inflammation). Transplanted hepatocytes were in proximity with liver cells that expressed prostaglandin-endoperoxide synthases. The number of engrafted hepatocytes increased in rats given naproxen or celecoxib before transplantation but not in rats given furegrelate (an inhibitor of thromboxane synthase) or clopodigrel (an antiplatelet drug). Naproxen and celecoxib did not prevent hepatic ischemia or activation of neutrophils, Kupffer cells, or inflammatory cytokines, but they did induce hepatic stellate cells to express cytoprotective genes, vascular endothelial growth factor and hepatocyte growth factor, and matrix-type metalloproteinases and tissue inhibitor of metalloproteinase-1, which regulate hepatic remodeling. Conclusions: Activation of cyclooxygenase pathways interferes with engraftment of transplanted hepatocytes in the liver. Pharmacologic blockade of prostaglandin-endoperoxide synthases stimulated hepatic stellate cells and improved cell engraftment.",
author = "Yuta Enami and Sriram Bandi and Sorabh Kapoor and Natan Krohn and Brigid Joseph and Sanjeev Gupta",
year = "2009",
month = "6",
doi = "10.1053/j.gastro.2009.03.003",
language = "English (US)",
volume = "136",
pages = "2356--2364",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Hepatic Stellate Cells Promote Hepatocyte Engraftment in Rat Liver After Prostaglandin-Endoperoxide Synthase Inhibition

AU - Enami, Yuta

AU - Bandi, Sriram

AU - Kapoor, Sorabh

AU - Krohn, Natan

AU - Joseph, Brigid

AU - Gupta, Sanjeev

PY - 2009/6

Y1 - 2009/6

N2 - Background & Aims: Hepatic inflammation occurs immediately after cells are transplanted to the liver, but the mechanisms that underlie this process are not fully defined. We examined cyclooxygenase pathways that mediate hepatic inflammation through synthesis of prostaglandins, prostacyclins, thromboxanes, and other prostanoids following transplantation of hepatocytes. Methods: We transplanted F344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient F344 rats. Changes in cyclooxygenase pathways were analyzed, and specific pathways were blocked pharmacologically; the effects on cell engraftment and native liver cells were determined. Results: Transplantation of hepatocytes induced hepatic expression of prostaglandin-endoperoxide synthases 1 and 2, which catalyze production of prostaglandin H2, as well as the downstream factor thromboxane synthase, which produces thromboxane A2 (a regulator of vascular and platelet responses in inflammation). Transplanted hepatocytes were in proximity with liver cells that expressed prostaglandin-endoperoxide synthases. The number of engrafted hepatocytes increased in rats given naproxen or celecoxib before transplantation but not in rats given furegrelate (an inhibitor of thromboxane synthase) or clopodigrel (an antiplatelet drug). Naproxen and celecoxib did not prevent hepatic ischemia or activation of neutrophils, Kupffer cells, or inflammatory cytokines, but they did induce hepatic stellate cells to express cytoprotective genes, vascular endothelial growth factor and hepatocyte growth factor, and matrix-type metalloproteinases and tissue inhibitor of metalloproteinase-1, which regulate hepatic remodeling. Conclusions: Activation of cyclooxygenase pathways interferes with engraftment of transplanted hepatocytes in the liver. Pharmacologic blockade of prostaglandin-endoperoxide synthases stimulated hepatic stellate cells and improved cell engraftment.

AB - Background & Aims: Hepatic inflammation occurs immediately after cells are transplanted to the liver, but the mechanisms that underlie this process are not fully defined. We examined cyclooxygenase pathways that mediate hepatic inflammation through synthesis of prostaglandins, prostacyclins, thromboxanes, and other prostanoids following transplantation of hepatocytes. Methods: We transplanted F344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient F344 rats. Changes in cyclooxygenase pathways were analyzed, and specific pathways were blocked pharmacologically; the effects on cell engraftment and native liver cells were determined. Results: Transplantation of hepatocytes induced hepatic expression of prostaglandin-endoperoxide synthases 1 and 2, which catalyze production of prostaglandin H2, as well as the downstream factor thromboxane synthase, which produces thromboxane A2 (a regulator of vascular and platelet responses in inflammation). Transplanted hepatocytes were in proximity with liver cells that expressed prostaglandin-endoperoxide synthases. The number of engrafted hepatocytes increased in rats given naproxen or celecoxib before transplantation but not in rats given furegrelate (an inhibitor of thromboxane synthase) or clopodigrel (an antiplatelet drug). Naproxen and celecoxib did not prevent hepatic ischemia or activation of neutrophils, Kupffer cells, or inflammatory cytokines, but they did induce hepatic stellate cells to express cytoprotective genes, vascular endothelial growth factor and hepatocyte growth factor, and matrix-type metalloproteinases and tissue inhibitor of metalloproteinase-1, which regulate hepatic remodeling. Conclusions: Activation of cyclooxygenase pathways interferes with engraftment of transplanted hepatocytes in the liver. Pharmacologic blockade of prostaglandin-endoperoxide synthases stimulated hepatic stellate cells and improved cell engraftment.

UR - http://www.scopus.com/inward/record.url?scp=66449108330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449108330&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2009.03.003

DO - 10.1053/j.gastro.2009.03.003

M3 - Article

C2 - 19303017

AN - SCOPUS:66449108330

VL - 136

SP - 2356

EP - 2364

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -